Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) is a clinical-stage biopharmaceutical company focused on integrin-based therapeutics for fibrotic diseases, solid tumors and muscular dystrophies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Pliant’s clinical programs and corporate strategy evolve over time.
In its recent press releases, Pliant has highlighted several key themes. The company has reported interim and ongoing data from a Phase 1, open-label, dose-escalation trial of PLN-101095, an oral dual-selective inhibitor of integrins αvβ8 and αvβ1, in patients with advanced or metastatic solid tumors that are resistant or refractory to immune checkpoint inhibitors. These updates describe antitumor activity, including partial and complete responses in certain dose cohorts when PLN-101095 is combined with pembrolizumab, as well as safety and pharmacokinetic observations.
Pliant’s news flow has also covered developments in its bexotegrast (PLN-74809) program in idiopathic pulmonary fibrosis, including the termination and close-out of the BEACON-IPF Phase 2b/3 trial and the company’s decision to discontinue development of bexotegrast in IPF after reviewing safety and efficacy data. Additional communications have described scientific presentations at medical conferences, such as the American Thoracic Society International Conference, where the company has shared clinical and preclinical data related to fibrosis and biomarkers.
Corporate updates, including workforce and operational realignments, financial results and changes in executive roles, are also part of Pliant’s news record. Investors and followers of PLRX can use this page to review these categories of news—clinical trial updates, scientific presentations, program decisions and corporate announcements—in one place and revisit past disclosures as needed.
Pliant Therapeutics, a clinical stage biotechnology company, will participate in the 20th Annual Needham Healthcare Conference from April 12-15, 2021. CEO Bernard Coulie will join a fireside chat with analyst Joseph Stringer on April 13, 2021, at 12:45 p.m. EDT. The event will be accessible via their website's Investors & Media page and will be available for 90 days. Pliant is focused on novel therapies for fibrosis, with candidates PLN-74809 and PLN-1474 in development for IPF, PSC, and liver fibrosis related to NASH.
Pliant Therapeutics (Nasdaq: PLRX) has resumed its PLN-74809 Phase 2a PET imaging trial, with preliminary results expected in the first half of 2021. The company reported strong progress in their Phase 2a trials for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), anticipated to complete enrollment by late 2021 and early 2022, respectively. Financially, R&D expenses rose to $17.9 million, leading to a net loss of $19.0 million, while cash reserves stood at $276.9 million, sufficient for operations into 2023.
Pliant Therapeutics (Nasdaq: PLRX) announced the successful completion of the Phase 1 trial for PLN-1474, a selective integrin αvβ1 inhibitor aimed at treating nonalcoholic steatohepatitis (NASH) with liver fibrosis. The trial, involving 84 healthy volunteers, demonstrated the drug's rapid absorption and tolerability without significant adverse effects. Following the trial, PLN-1474 is now under the stewardship of Novartis, per their 2019 Collaboration and License Agreement, which includes significant milestone payments and royalties for Pliant.
Pliant Therapeutics, a clinical stage biotechnology company focused on fibrosis treatment, has announced participation in key virtual investor events. Management will take part in the Cowen 41st Annual Health Care Conference from March 1-4, 2021, with a panel discussion led by President and CEO Bernard Coulie on March 1 at 10:30 a.m. ET. Additionally, they will engage with investors on March 17 during Citi's 2021 Winter West Coast Biotech Virtual Bus Tour. Pliant's lead drug candidate is PLN-74809, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis.
Pliant Therapeutics (Nasdaq: PLRX) announced the appointment of Dr. David Pyott to its Board of Directors, strengthening its leadership as the company advances its clinical stage portfolio. Dr. Pyott, former Chairman and CEO of Allergan, brings over 30 years of pharmaceutical experience, transforming Allergan into a global leader. He aims to support Pliant in developing innovative treatments for fibrosis. Pliant's lead candidate, PLN-74809, targets idiopathic pulmonary fibrosis and primary sclerosing cholangitis, with ongoing Phase 2a trials.
Pliant Therapeutics (Nasdaq: PLRX) has appointed Gregory P. Cosgrove, M.D., as Vice President of Clinical Development. Dr. Cosgrove will spearhead the strategic execution of the Idiopathic Pulmonary Fibrosis (IPF) clinical development program for PLN-74809, a dual selective inhibitor currently in Phase 2a trials. His extensive experience in pulmonary fibrosis research is expected to enhance Pliant's clinical efforts. PLN-74809 has received Orphan Drug Designation from the FDA for both IPF and primary sclerosing cholangitis.
Pliant Therapeutics (Nasdaq: PLRX) announced its participation in the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The company will feature a fireside chat with CEO Bernard Coulie on November 23, 2020, at 10:00 AM ET, available on their website. Pliant focuses on developing therapies for fibrosis, with lead candidate PLN-74809 in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The session will be archived for 90 days post-event.
Pliant Therapeutics (Nasdaq: PLRX) reported its Q3 2020 results, highlighting significant progress in clinical programs despite COVID-19 challenges. The company successfully executed its IPO and advanced multiple indications in its pipeline, notably PLN-74809 for idiopathic pulmonary fibrosis and COVID-19 related ARDS. Financially, the company experienced related party revenue of $4.8 million, with R&D expenses rising to $16.9 million, leading to a net loss of $16.5 million. Pliant maintains a strong cash position of $294 million, sufficient to fund operations into 2023.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) will present a poster at The Liver Meeting® 2020, hosted by AASLD, from November 13-16, 2020. The poster, titled "Profiling Fibrosis Regression in a Rat Model of Non-Alcoholic Steatohepatitis" (Abstract #0321), will be available online for registered participants. Pliant, focused on fibrosis treatment, has two main candidates: PLN-74809, in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and PLN-1474, in Phase 1 trials for liver fibrosis associated with NASH.
Pliant Therapeutics (Nasdaq: PLRX) has appointed Mike Ouimette as the new general counsel and corporate secretary. Bringing over 20 years of legal expertise, Ouimette previously held executive positions at Portola Pharmaceuticals and Onyx Pharmaceuticals. His appointment aims to enhance Pliant's legal and regulatory strategies as the company progresses its lead drug candidate, PLN-74809, through Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Pliant focuses on developing innovative therapies for treating fibrosis.